A couple of years ago, I published a post on 5 API Regulatory Challenges to Avoid, and it was interesting to look over the list and contemplate what updates I’d…
I was asked recently what a contract manufacturer such as Neuland Labs saw as the key differences with orphan drug projects. Neuland approaches orphan drug projects slightly differently from our…
Lately, I’ve been thinking about the subject of global API supply chain challenges. There have been a few articles recently, but it isn’t a new topic. Global drug supply chain…
Demand is steadily growing for pharmaceutical materials that contain micronized active drug substances (APIs) for inhalation and injectable delivery. Active pharmaceutical ingredients (APIs) are micronized for a number of reasons,…
In a recent issue of PharmTech, Agnes Shanley wrote an article on the specialty markets and services driving the growth of APIs in which we were featured. For me, the…
With technology racing onward, drugs are becoming more complex than ever before – along with their active ingredients and the processes that produce them. Different Challenges, Different Scales – The…
At its core, Neuland’s philosophy is to meet or exceed quality levels defined by the customer, while also meeting stringent international standards. With multiple customer projects in the works at…
With everything involved in bringing a drug to market, enlisting the services of an experienced CMO can prove to be a very worthy investment. Ideally, the relationship between a pharma…
In this post, we’ll look at a unique Prep-RP-HPLC method developed at Neuland Labs to achieve 10-fold increases in sample loadability. Despite advances in technology, there are only two ways…
In a post last month, we discussed the three types of peptide production techniques Neuland uses to cGMP manufacture peptide APIs and NCEs for clients. We also mentioned some of the…
